Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Paricalcitol
Drug ID BADD_D01676
Description Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Indications and Usage For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
Marketing Status Prescription; Discontinued
ATC Code H05BX02
DrugBank ID DB00910
KEGG ID D00930
MeSH ID C084656
PubChem ID 5281104
TTD Drug ID D0N1TP
NDC Product Code 25000-012; 70121-1036; 65862-938; 68382-331; 68513-1054; 25000-014; 66499-0019; 0409-1008; 63629-2452; 69452-145; 17478-033; 25000-017; 10888-8103; 0143-9625; 67457-692; 70121-1035; 49483-687; 43598-563; 55150-213; 48943-0033; 58032-1001; 55111-663; 70121-1034; 69452-146; 65862-937; 55150-214; 68382-330; 0143-9624; 11014-0053; 43598-564; 43598-565; 43598-562; 0074-9036; 55111-665; 63629-2453; 0074-1658; 55150-212; 10888-8102; 55150-215; 65162-822; 58272-192; 49483-689; 0409-1007; 65162-824; 49483-688; 65162-823; 55111-664; 69452-147; 11014-0048; 16729-310; 0074-9037; 16729-311; 70121-1033; 67457-380; 65862-936; 10888-8104; 0143-9596; 0074-4637; 14474-021
Synonyms paricalcitol | 19-nor-1alpha,25-dihydroxyvitamin D2 | 19-nor-1,25-(OH)2D2 | Zemplar | paricalcitol-d6
Chemical Information
Molecular Formula C27H44O3
CAS Registry Number 131918-61-1
SMILES CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionParathyroid hormone/parathyroid hormone-related peptide receptorQ03431T6771011576883; 9697664; 9808143
Adverse drug reactionAlkaline phosphatase, placental typeP05187Not Available11576883; 9697664; 9808143
Electrolyte imbalanceGastrin/cholecystokinin type B receptorP32239T0584912529809; 12073167; 9160584; 7619662
Iron and trace metal metabolism disordersParathyroid hormone/parathyroid hormone-related peptide receptorQ03431T6771011576883; 9697664; 9808143
Iron and trace metal metabolism disordersAlkaline phosphatase, placental typeP05187Not Available11576883; 9697664; 9808143
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chills15.05.03.016; 08.01.09.001--
Choking sensation22.02.05.002; 19.01.02.0020.008993%Not Available
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Colitis07.08.01.001--
Colon cancer07.21.01.001; 16.13.01.0010.005865%Not Available
Condition aggravated08.01.03.004--Not Available
Confusional state17.02.03.005; 19.13.01.001--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Cough22.02.03.001--
Death08.04.01.0013.611615%
Decubitus ulcer23.03.11.0060.002346%Not Available
Dehydration14.05.05.001--
Delirium19.13.02.001--
Depressed level of consciousness17.02.04.002--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diabetic ketoacidosis05.07.03.001; 14.07.03.001--Not Available
Diabetic retinopathy24.03.07.004; 14.07.01.002; 06.10.02.002; 05.07.01.0020.008993%Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug hypersensitivity10.01.01.001--Not Available
Dry mouth07.06.01.002--
Dysarthria17.02.08.001; 19.19.03.001--
Dysgeusia17.02.07.003; 07.14.03.001--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 12 Pages